Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis

High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis

J Neurol Neurosurg Psychiatry.

Goutman SA, Boss J, Patterson A, Mukherjee B, Batterman S, Feldman EL

doi: 10.1136/jnnp-2018-319785.

Amyotrophic Lateral Sclerosis

Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications

Lancet Neurol.

Chia R, Chiò A, Traynor BJ

doi: 10.1016/

Amyotrophic Lateral Sclerosis

Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis

JAMA Neurol.

Lunetta C, Lizio A, Maestri E, Sansone VA, Mora G, Miller RG, Appel SH, Chiò A

doi: 10.1001/jamaneurol.

Amyotrophic Lateral Sclerosis

Dysregulation of MicroRNAs and Target Genes Networks in Peripheral Blood of Patients With Sporadic Amyotrophic Lateral Sclerosis

Front Mol Neurosci.

Liguori M, Nuzziello N, Introna A, Consiglio A, Licciulli F, D'Errico E, Scarafino A, Distaso E, Simone IL

doi: 10.3389/fnmol.2018.00288.

Amyotrophic Lateral SclerosisDementia

Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease

JAMA Neurol.

Gaiani A, Martinelli I, Bello L, Querin G, Puthenparampil M, Ruggero S, Toffanin E, Cagnin A, Briani C, Pegoraro E, Sorarù G

doi: 10.1001/jamaneurol.

Amyotrophic Lateral Sclerosis

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

Lancet Neurol.

Writing Group, Edaravone (MCI-186) ALS 19 Study Group

doi: 10.1016/

Amyotrophic Lateral Sclerosis

Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes

JAMA Neurol.

Zhao W, Beers DR, Hooten KG, Sieglaff DH, Zhang A, Kalyana-Sundaram S, Traini CM, Halsey WS, Hughes AM, Sathe GM, Livi GP, Fan GH, Appel SH

doi: 10.1001/

Amyotrophic Lateral Sclerosis

Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias

J Neurol Neurosurg Psychiatry.

Mehta PR, Jones AR, Opie-Martin S, Shatunov A, Iacoangeli A, Al Khleifat A, Smith BN, Topp S, Morrison KE, Shaw PJ, Shaw CE, Morgan S, Pittman A, Al-Chalabi A

doi: 10.1136/jnnp-2018-319089.

Amyotrophic Lateral Sclerosis

Identification of a circulating miRNA signature in extracellular vesicles collected from amyotrophic lateral sclerosis patients

Brain Res.

Saucier D, Wajnberg G, Roy J, Beauregard AP, Chacko S, Crapoulet N, Fournier S, Ghosh A, Lewis SM, Marrero A, O'Connell C, Ouellette RJ, Jr Morin P

doi: 10.1016/j.brainres.

Related content

High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis

Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications

Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis

Dysregulation of MicroRNAs and Target Genes Networks in Peripheral Blood of Patients With Sporadic Amyotrophic Lateral Sclerosis

Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes

Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias

Identification of a circulating miRNA signature in extracellular vesicles collected from amyotrophic lateral sclerosis patients